Background: Inflammation is essential in cardiovascular disease (CVD)
development and progression. A novel inflammatory parameter, the systemic
inflammation response index (SIRI), has been proven to predict cancer prognosis
strongly. Little is known about the relationship between SIRI and outcomes in
patients with ST-segment elevation myocardial infarction (STEMI).
Methods: 1312 STEMI patients who underwent percutaneous coronary
intervention (PCI) in Beijing Anzhen hospital from January 2019 to December 2021
were analyzed. SIRI was calculated as
neutrophils monocytes/lymphocytes. Our
primary outcome was a 30-day major adverse event (MACE), including all-cause
mortality, non-fatal myocardial infarction (MI), stroke, incident heart failure
(HF), cardiogenic shock, and cardiac arrest. Results: Patients were
stratified into four groups according to quartiles of SIRI: SIRI 1.58 (n =
328), 1.58 SIRI 3.28 (n = 328), 3.28 SIRI 7.80 (n = 328),
SIRI 7.80 (n = 328). Higher SIRI was associated with a higher incidence
of the 30-day MACE. The rates of 30-day MACE were 6.1%, 8.8%, 12.8%, and
17.1% (p 0.001) for the lowest SIRI quartile to the highest
quartile, respectively. This association was consistent in the outcome of HF but
no other components. Higher SIRI indicated higher 30-day MACE incidence in most
participants except in those with very high inflammatory indicators. Subgroup
analysis showed this correlation was consistent in various subgroups
(p for interaction 0.05).
Conclusions: In patients with STEMI, higher SIRI indicated a higher
incidence of 30-day MACE, except for those with very high inflammatory
indicators. In most STEMI patients, SIRI might be a trustworthy indicator of
short-term prognosis.